You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

 

CME / ABIM MOC / CE

Current and Emerging Targeted Approaches for Treating Acute Myeloid Leukemia

  • Authors: Amir Fathi, MD; Laura Olson, RPh, BCOP, BCPS; Laura J. Zitella, MS, RN, ACNP-BC, AOCN
  • CME / ABIM MOC / CE Released: 1/6/2022
  • THIS ACTIVITY HAS EXPIRED
  • Valid for credit through: 1/6/2023
Start Activity


Target Audience and Goal Statement

This activity is intended for community-based hematologists/oncologists, nurses, nurse practitioners, and pharmacists.

The goal of this activity is to improve knowledge of current and emerging targeted therapies, and to promote greater competence when managing treatment and its associated side effects as part of a community-based AML care team treating patients with newly diagnosed or relapsed/refractory (R/R) AML.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Emerging targeted therapy approaches for treating AML
  • Have greater competence related to
    • Integrating FLT3 inhibitors into AML treatment plans
    • Utilizing IDH inhibitors for the treatment of AML
  • Demonstrate greater confidence in their ability to
    • Work within an interprofessional team to manage side effects of targeted AML therapies


Faculty

  • Amir Fathi, MD

    Associate Professor of Medicine
    Harvard Medical School
    Program Director, Center for Leukemia
    Massachusetts General Hospital
    Boston, Massachusetts

    Disclosures

    Disclosure: Amir Fathi, MD, has the following relevant financial relationships: 
    Advisor or consultant for: AbbVie; Amgen; Astellas; Blueprint; Celgene Servier; Foghorn; Genentech; Ipsen; Kura Kite; Seagen, Inc., formerly Seattle Genetics, Inc.
    Grants for clinical research from: AbbVie/Bristol Myers Squibb, formerly Celgene Servier, formerly Agios

  • Laura Olson, RPh, BCOP, BCPS

    Oncology Pharmacy Clinical Manager
    Virginia G. Piper Cancer Center Network 
    at Honor Health
    Scottsdale, Arizona

    Disclosures

    Disclosure: Laura Olson, RPh, BCOP, BCPS, has no relevant financial relationships. 

  • Laura J. Zitella, MS, RN, ACNP-BC, AOCN

    Hematology/Oncology Nurse Practitioner
    Associate Clinical Professor
    University of California San Francisco
    San Francisco, California

    Disclosures

    Disclosure: Laura J. Zitella, MS, RN, ACNP-BC, AOCN, has no relevant financial relationships.

Editors

  • Heather P. Friedman, MPH

    Medical Education Director, Medscape, LLC

    Disclosures

    Disclosure: Heather P. Friedman, MPH, has disclosed no relevant financial relationships.

  • Tristin Abair, PhD

    Senior Medical Writer, Medscape, LLC 

    Disclosures

    Disclosure: Tristin Abair, PhD, has disclosed no relevant financial relationships.

CME, CE Reviewer/Nurse Planner

  • Stephanie Corder, ND, RN, CHCP

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Disclosure: Stephanie Corder, ND, RN, CHCP, has disclosed no relevant financial relationships.

None of the nonfaculty planners for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.

Mitigation 

All of the relevant financial relationships listed for these individuals have been mitigated. 


Accreditation Statements



In support of improving patient care, Medscape LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    Contact This Provider

    For Nurses

  • Awarded 1.0 contact hour(s) of continuing nursing education for RNs and APNs; 1.0 contact hours are in the area of pharmacology.

    Contact This Provider

    For Pharmacists

  • Medscape, LLC designates this continuing education activity for 1.0 contact hour(s) (0.100 CEUs) (Universal Activity Number JA0007105-0000-21-579-H01-P).

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read about the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or print it out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC / CE

Current and Emerging Targeted Approaches for Treating Acute Myeloid Leukemia

Authors: Amir Fathi, MD; Laura Olson, RPh, BCOP, BCPS; Laura J. Zitella, MS, RN, ACNP-BC, AOCNFaculty and Disclosures
THIS ACTIVITY HAS EXPIRED

CME / ABIM MOC / CE Released: 1/6/2022

Valid for credit through: 1/6/2023

processing....

Contents of This CME Activity

All sections of this activity are required for credit.

Perspectives on the Role of FLT3 Inhibition in AML

Get expert insight on how to best integrate FLT3 inhibitors into the treatment of patients with AML.
Amir Fathi, MD; Laura Olson, RPh, BCOP, BCPS; Laura J. Zitella, MS, RN, ACNP-BC, AOCN

Optimizing the Use of IDH Inhibitors in Patients with AML

Get expert insight on the appropriate incorporation of IDH inhibitors into patient care.
Amir Fathi, MD; Laura Olson, RPh, BCOP, BCPS; Laura J. Zitella, MS, RN, ACNP-BC, AOCN

Novel Combination Approaches and Targeted Therapies

Get expert insight on emerging targeted treatment approaches for AML, including combinations and novel targeted agents.
Amir Fathi, MD; Laura Olson, RPh, BCOP, BCPS; Laura J. Zitella, MS, RN, ACNP-BC, AOCN

Educational Impact Challenge

The goal of this activity is to improve knowledge of current and emerging targeted therapies, and to promote greater competence when managing treatment and its associated side effects as part of a community-based AML care team treating patients with newly diagnosed or R/R AML.

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and provide an opportunity for you to compare your answers with those of your peers.

  • Print